Omburtamab (8H9) for CNS Relapse
In this session, Dr. Kim Kramer, talks about challenges in the field of pediatric oncology including brand metastases from Neuroblastoma, and how this relates to other high-risk and recurrent common pediatric solid tumours, including Medulloblastoma. She shares information on the treatment of Omburtamab (8H9) for CNS relapse, including practical information for families. This is a recorded presentation from the 2020 symposium.
In this session, Dr. Kim Kramer, talks about challenges in the field of pediatric oncology including brand metastases from Neuroblastoma, and how this relates to other high-risk and recurrent common pediatric solid tumours, including Medulloblastoma. She shares information on the treatment of Omburtamab (8H9) for CNS relapse, including practical information for families. This is a recorded presentation from the 2020 symposium.